U.S. Markets closed

InVivo Therapeutics Holdings Corp. (NVIV)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.20+0.10 (+4.76%)
At close: 4:00PM EDT
People also watch
AVXLCURONCSADXSATHX

InVivo Therapeutics Holdings Corp.

One Kendall Square
Suite B14402
Cambridge, MA 02139
United States
617-863-5500
http://www.invivotherapeutics.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees37

Key Executives

NameTitlePayExercisedAge
Mr. Mark D. PerrinChairman and Chief Exec. Officer741.94kN/A60
Dr. Thomas R. Ulich M.D.Chief Scientific Officer463.28kN/A64
Ms. Pamela J. StahlChief Commercial Officer660.94kN/A51
Dr. Robert S. Langer Jr., Ph.D., Sc.D.Co-Founder and Member of Scientific Advisory BoardN/AN/A68
Dr. Joseph Philip Vacanti M.D.Co-FounderN/AN/A68
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, focus on developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for acute SCI; and Therapeutic Trails injection program for the treatment of chronic SCI. The company was founded in 2005 and is based in Cambridge, Massachusetts.

Corporate Governance

InVivo Therapeutics Holdings Corp.’s ISS Governance QualityScore as of July 1, 2017 is 8. The pillar scores are Audit: 5; Board: 5; Shareholder Rights: 6; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.